PLX5622 是高度选择性的、能透过血脑屏障的、口服有效的 CSF1R 抑制剂 (IC₅₀= 0.016 µM; K_i= 5.9 nM)，可用于病程发展前和过程中，扩大的和特异性的小胶质细胞的消除。PLX5622 具有较好的药理学特性。

PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC 50 =0.016 μM; K i =5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals.

Solid

IC50: 0.016 μM (CSF1R); Ki: 5.9 nM (CSF1R)

PLX5622 (1-20 μM; 3 days) effectively depletes microglia without affecting oligodendrocytes or astrocytes in cerebellar slices. PLX5622 (4 μM; 3 days) causes a 30-40% reduction in NG2+ or PDGFRα+ cells, and this increased to 90-95% at 20 μM. No reduction of NG2+ or PDGFRα+ OPCs is observed in slices exposed to 1 μM or 2 μM PLX5622 despite robust (~95%) depletion of the microglial cells. has not independently confirmed the accuracy of these methods. They are for reference only.

Pharmacodynamics of PLX5622 in preclinical studies
PLX5622 (1200 ppm; chow; for 3 weeks or 3 days; adult C57/Bl6 wild type mice) leads to around 80% of microglia lost after 3 days of treatment and a 99% microglia loss after 3 weeks of treatment. PLX5622 (adult C57/Bl6 wild type mice aged 3 months; diet for 3 weeks) decreases microglia in cortex, striatum, cerebellum and hippocampus.
PLX5622 (50?mg/kg; intraperitoneal injection; once (neonatal rat) or twice (adult rat) a day; for a total of 14 days) depletes microglia by 80-90% within 3 days of treatment, which increases to > 90% by 7 days. After 14 days of PLX5622 treatment, microglia is depleted by > 96% in both neonates and adults while preserving baseline astrocyte quantity. (A single daily injection of 0.65% PLX5622 suspended in 5% dimethyl sulfoxide and 20% Kolliphor RH40 in 0.01?

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimers disease model. Nat Commun. 2019 Aug 21;10(1):3758.
[2]. Lee S, et al. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. Mol Pain. 2018 Jan-Dec;14:1744806918764979.

In Vitro: DMSO : 25 mg/mL (63.23 mM; ultrasonic and warming and heat to 80°C)Ethanol : 3.33 mg/mL (8.42 mM; ultrasonic and warming and heat to 60°C)H₂O : < 0.1 mg/mL (insoluble)